Literature DB >> 30474955

Analgesic Effects of the GIRK Activator, VU0466551, Alone and in Combination with Morphine in Acute and Persistent Pain Models.

Kristopher K Abney1, Michael Bubser2,3, Yu Du2, Krystian A Kozek2, Thomas M Bridges3, Craig W Linsdley2,3, J Scott Daniels4, Ryan D Morrison4, Kevin Wickman5, Corey R Hopkins6, Carrie K Jones2,3, C David Weaver2,7.   

Abstract

G protein-gated inwardly rectifying potassium (GIRK) channels are potassium-selective ion channels. As their name suggests, GIRK channels are effectors of Gi/o G protein-couple receptors whereby activation of these GPCRs leads to increased GIRK channel activity resulting in decreased cellular excitability. In this way, GIRK channels play diverse roles in physiology as effectors of Gi/o-coupled GPCRs: peacemaking in the heart rate, modulation of hormone secretion in endocrine tissues, as well as numerous CNS functions including learning, memory, and addiction/reward. Notably, GIRK channels are widely expressed along the spinothalamic tract and are positioned to play roles in both ascending and descending pain pathways. More notably, GIRK channel knockout and knock-down studies have found that GIRK channels play a major role in the action of opioid analgesics which act predominantly through Gi/o-coupled, opioid-activated GPCRs (e.g., μ-opioid receptors). Recent advances in GIRK channel pharmacology have led to the development of small molecules that directly and selectively activate GIRK channels. Based on research implicating the involvement of GIRK channels in pain pathways and as effectors of opioid analgesics, we conducted a study to determine whether direct pharmacological activation of GIRK channels could produce analgesic efficacy and/or augment the analgesic efficacy morphine, an opioid receptor agonist capable of activating μ-opioid receptors as well as other opioid receptor subtypes. In the present study, we demonstrate that the small-molecule GIRK activator, VU0466551, has analgesic effects when dosed alone or in combination with submaximally effective doses of morphine.

Entities:  

Keywords:  GIRK; activator; analgesia; formalin assay; hot plate; morphine

Mesh:

Substances:

Year:  2018        PMID: 30474955      PMCID: PMC6765219          DOI: 10.1021/acschemneuro.8b00370

Source DB:  PubMed          Journal:  ACS Chem Neurosci        ISSN: 1948-7193            Impact factor:   4.418


  38 in total

1.  Diverse trafficking patterns due to multiple traffic motifs in G protein-activated inwardly rectifying potassium channels from brain and heart.

Authors:  Dzwokai Ma; Noa Zerangue; Kimberly Raab-Graham; Sharon R Fried; Yuh Nung Jan; Lily Yeh Jan
Journal:  Neuron       Date:  2002-02-28       Impact factor: 17.173

2.  Involvement of G-protein-activated inwardly rectifying K (GIRK) channels in opioid-induced analgesia.

Authors:  K Ikeda; T Kobayashi; T Kumanishi; H Niki; R Yano
Journal:  Neurosci Res       Date:  2000-09       Impact factor: 3.304

3.  Associations between KCNJ6 (GIRK2) gene polymorphisms and pain-related phenotypes.

Authors:  Stephen Bruehl; Jerod S Denton; Daniel Lonergan; Mary Ellen Koran; Melissa Chont; Christopher Sobey; Shanik Fernando; William S Bush; Puneet Mishra; Tricia A Thornton-Wells
Journal:  Pain       Date:  2013-08-28       Impact factor: 6.961

4.  Analgesia and motor activity elicited by morphine and enkephalins in two inbred strains of mice.

Authors:  V Frigeni; F Bruno; A Carenzi; G Racagni; V Santini
Journal:  J Pharm Pharmacol       Date:  1978-05       Impact factor: 3.765

Review 5.  Signalling via the G protein-activated K+ channels.

Authors:  N Dascal
Journal:  Cell Signal       Date:  1997-12       Impact factor: 4.315

6.  Association between KCNJ6 (GIRK2) gene polymorphism rs2835859 and post-operative analgesia, pain sensitivity, and nicotine dependence.

Authors:  Daisuke Nishizawa; Ken-ichi Fukuda; Shinya Kasai; Yasukazu Ogai; Junko Hasegawa; Naomi Sato; Hidetaka Yamada; Fumihiko Tanioka; Haruhiko Sugimura; Masakazu Hayashida; Kazutaka Ikeda
Journal:  J Pharmacol Sci       Date:  2014-10-25       Impact factor: 3.337

7.  Ethanol Dependence Abolishes Monoamine and GIRK (Kir3) Channel Inhibition of Orbitofrontal Cortex Excitability.

Authors:  Sudarat Nimitvilai; Marcelo F Lopez; Patrick J Mulholland; John J Woodward
Journal:  Neuropsychopharmacology       Date:  2017-01-31       Impact factor: 7.853

8.  Discovery of 'molecular switches' within a GIRK activator scaffold that afford selective GIRK inhibitors.

Authors:  Wandong Wen; Wenjun Wu; Ian M Romaine; Kristian Kaufmann; Yu Du; Gary A Sulikowski; C David Weaver; Craig W Lindsley
Journal:  Bioorg Med Chem Lett       Date:  2013-06-20       Impact factor: 2.823

9.  Mechanisms underlying the activation of G-protein-gated inwardly rectifying K+ (GIRK) channels by the novel anxiolytic drug, ML297.

Authors:  Nicole Wydeven; Ezequiel Marron Fernandez de Velasco; Yu Du; Michael A Benneyworth; Matthew C Hearing; Rachel A Fischer; Mark John Thomas; C David Weaver; Kevin Wickman
Journal:  Proc Natl Acad Sci U S A       Date:  2014-07-07       Impact factor: 11.205

10.  The rat paw formalin test: comparison of noxious agents.

Authors:  Helen Wheeler-Aceto; Frank Porreca; Alan Cowan
Journal:  Pain       Date:  1990-02       Impact factor: 6.961

View more
  7 in total

1.  VU0810464, a non-urea G protein-gated inwardly rectifying K+ (Kir 3/GIRK) channel activator, exhibits enhanced selectivity for neuronal Kir 3 channels and reduces stress-induced hyperthermia in mice.

Authors:  Baovi N Vo; Kristopher K Abney; Allison Anderson; Ezequiel Marron Fernandez de Velasco; Michael A Benneyworth; John Scott Daniels; Ryan D Morrison; Corey R Hopkins; Charles David Weaver; Kevin Wickman
Journal:  Br J Pharmacol       Date:  2019-05-30       Impact factor: 8.739

2.  Discovery, synthesis and biological characterization of a series of N-(1-(1,1-dioxidotetrahydrothiophen-3-yl)-3-methyl-1H-pyrazol-5-yl)acetamide ethers as novel GIRK1/2 potassium channel activators.

Authors:  Swagat Sharma; Lauren Lesiak; Christopher D Aretz; Yu Du; Sushil Kumar; Nagsen Gautam; Yazen Alnouti; Nikilesh V Dhuria; Yashpal S Chhonker; C David Weaver; Corey R Hopkins
Journal:  RSC Med Chem       Date:  2021-06-21

Review 3.  Neuronal G protein-gated K+ channels.

Authors:  Haichang Luo; Ezequiel Marron Fernandez de Velasco; Kevin Wickman
Journal:  Am J Physiol Cell Physiol       Date:  2022-06-15       Impact factor: 5.282

4.  G-Protein-Gated Inwardly Rectifying Potassium (Kir3/GIRK) Channels Govern Synaptic Plasticity That Supports Hippocampal-Dependent Cognitive Functions in Male Mice.

Authors:  Souhail Djebari; Guillermo Iborra-Lázaro; Sara Temprano-Carazo; Irene Sánchez-Rodríguez; Mauricio O Nava-Mesa; Alejandro Múnera; Agnès Gruart; José M Delgado-García; Lydia Jiménez-Díaz; Juan D Navarro-López
Journal:  J Neurosci       Date:  2021-07-14       Impact factor: 6.167

Review 5.  Advances in Targeting GIRK Channels in Disease.

Authors:  Yulin Zhao; Isabel Gameiro-Ros; Ian W Glaaser; Paul A Slesinger
Journal:  Trends Pharmacol Sci       Date:  2021-01-16       Impact factor: 14.819

Review 6.  Next-generation inward rectifier potassium channel modulators: discovery and molecular pharmacology.

Authors:  C David Weaver; Jerod S Denton
Journal:  Am J Physiol Cell Physiol       Date:  2021-04-07       Impact factor: 5.282

7.  AsKC11, a Kunitz Peptide from Anemonia sulcata, Is a Novel Activator of G Protein-Coupled Inward-Rectifier Potassium Channels.

Authors:  Dongchen An; Ernesto Lopes Pinheiro-Junior; László Béress; Irina Gladkikh; Elena Leychenko; Eivind A B Undheim; Steve Peigneur; Jan Tytgat
Journal:  Mar Drugs       Date:  2022-02-15       Impact factor: 5.118

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.